Literature DB >> 11843383

Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes.

K G Cooper1, S A Jack, D E Parkin, A M Grant.   

Abstract

OBJECTIVE: To assess clinical status, changes in health related quality of life, and subsequent management five years after medical management or transcervical resection of the endometrium for treatment of heavy menstrual loss.
DESIGN: Five year follow up using postal questionnaires and operative databank review.
SETTING: Gynaecology department of a large UK teaching hospital. POPULATION: Women referred to the gynaecologist for treatment of heavy menstrual loss.
METHODS: Eligible women, without a treatment preference, were randomised equally to either medical treatment or transcervical resection of the endometrium. MAIN OUTCOME MEASURES: Women's satisfaction with treatment, menstrual status, changes in health related quality of life, and additional treatments received at five years.
RESULTS: One hundred and forty-four patients completed questionnaires, achieving 77% follow up (medical n = 71/94; transcervical resection of the endometrium n = 73/93). At five-year follow up, 7/71 (10%) of those randomised to the medical arm still used medical treatment, while 72/94 (77%) had undergone surgical treatment and 17/94 (18%) a hysterectomy. Twenty-five (27%) women allocated to transcervical resection of the endometrium had undergone further surgery, 18/93 (19%) a hysterectomy. At five years women initially randomised to medical treatment were significantly less likely to be totally satisfied (P < 0.01, difference 21%, 95% CI -37% to -4%), or to recommend their allocated treatment to a friend (P < 0.001, difference 59%, 95% CI -73% to -45%). Bleeding and pain scores were similar in both groups and highly significantly reduced. Significantly more women in the transcervical resection of the endometrium arm had no bleeding or very light bleeding (P < 0.02, difference -22%, CI -31% to -4%), and they had significantly less days heavy bleeding (P < 0.02). Short Form 36 health survey scores were significantly improved from baseline for all eight health scales in the transcervical resection of the endometrium arm, and four in the medical arm.
CONCLUSIONS: A policy of immediate transcervical resection of the endometrium for women referred to a gynaecologist for treatment of heavy menstrual loss achieves higher levels of satisfaction, better menstrual status, and greater improvements in health related quality of life than medical treatment. In addition, transcervical resection of the endometrium is safe and does not lead to an increase in the number of hysterectomies. An effective endometrial ablative technique should be offered to all eligible women seeking treatment of their heavy menses from a gynaecologist.

Entities:  

Mesh:

Year:  2001        PMID: 11843383     DOI: 10.1111/j.1471-0528.2001.00275.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  11 in total

1.  Therapy of heavy menstrual bleeding in Korea: Subanalysis and results from a multinational clinical trial in the Asian region investigating the levonorgestrel-releasing intrauterine system versus conventional therapy.

Authors:  Byung Seok Lee; Xu Ling; Shaheena Asif; Peter Kraemer; Jens Ulrich Hanisch; Pirjo Inki; Jung Eun Lee
Journal:  Obstet Gynecol Sci       Date:  2015-03-16

Review 2.  Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients.

Authors:  L J Middleton; R Champaneria; J P Daniels; S Bhattacharya; K G Cooper; N H Hilken; P O'Donovan; M Gannon; R Gray; K S Khan; J Abbott; J Barrington; S Bhattacharya; M Y Bongers; J-L Brun; R Busfield; M Sowter; T J Clark; J Cooper; K G Cooper; S L Corson; K Dickersin; N Dwyer; M Gannon; J Hawe; R Hurskainen; W R Meyer; H O'Connor; S Pinion; A M Sambrook; W H Tam; I A A van Zon-Rabelink; E Zupi
Journal:  BMJ       Date:  2010-08-16

3.  Thermal balloon endometrial ablation for dysfunctional uterine bleeding: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2004-09-01

Review 4.  Benefits and risks of pharmacological agents used for the treatment of menorrhagia.

Authors:  Samendra Nath Roy; Siladitya Bhattacharya
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding.

Authors:  Robert L Dood; Clarisa R Gracia; Mary D Sammel; Kevin Haynes; Suneeta Senapati; Brian L Strom
Journal:  J Minim Invasive Gynecol       Date:  2014-02-28       Impact factor: 4.137

Review 6.  Abnormal uterine bleeding: a review of patient-based outcome measures.

Authors:  Kristen A Matteson; Lori A Boardman; Malcolm G Munro; Melissa A Clark
Journal:  Fertil Steril       Date:  2008-07-16       Impact factor: 7.329

Review 7.  Surgery versus medical therapy for heavy menstrual bleeding.

Authors:  Jane Marjoribanks; Anne Lethaby; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2016-01-29

Review 8.  Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis.

Authors:  T E Roberts; A Tsourapas; L J Middleton; R Champaneria; J P Daniels; K G Cooper; S Bhattacharya; P M Barton
Journal:  BMJ       Date:  2011-04-26

9.  Usual medical treatments or levonorgestrel-IUS for women with heavy menstrual bleeding: long-term randomised pragmatic trial in primary care.

Authors:  Joe Kai; Lee Middleton; Jane Daniels; Helen Pattison; Konstantinos Tryposkiadis; Janesh Gupta
Journal:  Br J Gen Pract       Date:  2016-10-10       Impact factor: 5.386

Review 10.  A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma.

Authors:  Terrence D Lewis; Minnie Malik; Joy Britten; Angelo Macapagal San Pablo; William H Catherino
Journal:  Biomed Res Int       Date:  2018-01-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.